Pelvic Inflammatory Disease in COVID-19 Era

Recruiting

• Conditions: Pelvic Inflammatory Disease

• Registration Number: NCT05648747
• Lead Sponsor: Università degli Studi di Ferrara

Brief Summary

The goal of this retrospective cohort study is to to scrutinize the impact of coronavirus disease 2019 (COVID-19) on incidence, demography and patient characteristics in Pelvic Inflammatory Disease comparing with the equal time duration, before and after lockdown was initiated in the country.

The main aim of this study was to compare the demographic and clinical parameters between two cohorts before the onset of lockdown and within the pandemic.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-12
• Study First Submitted: 2022-12-09
• Study First Submitted QC: 2022-12-09
• Last Update Submitted: 2022-12-09
• Study First Posted: 2022-12-13
• Last Update Posted: 2022-12-13
• Study Start: 2023-01-01
• Primary Completion: 2024-01-01
• Study Completion: 2024-01-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 300

Inclusion Criteria

Pelvic Inflammatory disease

Exclusion Criteria

Pregnancy Oncologic disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of pelvic inflammatory disease (PID)	baseline, pre-surgery	The primary outcome measure was the occurrence of PID defined as abscess observed in computed tomography or a description of gangrenous salpingitis assessed by pathological reports.

Trial Locations

Locations (1)

Section of Obstetrics and Gynecology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy; 🇮🇹 Ferrara, Italy